Hennion & Walsh Asset Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 197,401 shares of VRDN stock, worth $3.76 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
197,401
Previous 178,855
10.37%
Holding current value
$3.76 Million
Previous $2.33 Million
93.04%
% of portfolio
0.22%
Previous 0.12%
Shares
6 transactions
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$90.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$84.1 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$73.9 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$71.4 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$65.6 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $759M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...